HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction

Back

ESC Professional Premium Access

HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction

Session: Therapeutic strategies to combat vascular disease

Topic: Vascular Diseases

Speaker: Doctor J. Schoelermann (Montreal, CA)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Julia Schoelermann

35Pharma Inc., Montreal (Canada)

0 follower

7 more presentations in this session

Atheroprotective CD40-TRAF6 inhibitors: translational pipeline towards a clinical application

Speaker: Doctor V. Bazioti (Munich, DE)

Characterization of AT-02, a pan-amyloid-binding peptide fusion immunoglobulin with high binding potency, complement activation, and immune cell stimulation

Speaker: Professor J. Wall (Knoxville, US)

Dapagliflozin downregulates G protein-coupled receptor Kinase-2 and upregulates regulator of g protein signaling-4 in adrenals to exert sympatholysis in heart failure

Speaker: Associate Professor A. Lymperopoulos (Fort Lauderdale, US)

Effective cardiac mRNA delivery using lipid nanoparticles

Speaker: Ms M. Labonia (Utrecht, NL)

Dapagliflozin decreases atherosclerotic plaque instability via regulating macrophage pyroptosis

Speaker: Doctor L. Xu (Shanghai, CN)

Access the full session

Therapeutic strategies to combat vascular disease

Speakers: Doctor J. Schoelermann, Doctor V. Bazioti, Professor J. Wall, Associate Professor A. Lymperopoulos, Ms M. Labonia...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources